Skip to main content

Advertisement

Table 4 Multiple-adjusted HRs for OS by baseline BMI level, stratified by covariates

From: Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study

Stratification covariate No. of patients Underweight (HRa) Normal weight [HR (95% CI)a] Overweight/obese [HR (95% CI)a] P b
Age (years) 0.675
 <45 419 1.0 1.01 (0.74–1.38) 0.74 (0.50–1.09)  
 ≥45 400 1.0 0.76 (0.55–1.06) 0.54 (0.37–0.79)  
Sex 0.680
 Men 681 1.0 0.82 (0.64–1.04) 0.59 (0.44–0.79)  
 Women 138 1.0 1.29 (0.67–2.45) 0.93 (0.45–1.94)  
UICC T category 0.471
 T1–2 369 1.0 0.84 (0.60–1.17) 0.78 (0.52–1.17)  
 T3–4 450 1.0 0.88 (0.65–1.19) 0.49 (0.34–0.70)  
UICC N category 0.501
 N0–1 417 1.0 0.83 (0.61–1.14) 0.55 (0.37–0.82)  
 N2–3 402 1.0 0.86 (0.60–1.18) 0.67 (0.46–0.98)  
Metastasis onset 0.551
 Synchronous 272 1.0 0.94 (0.60–1.49) 0.55 (0.33–0.90)  
 Metachronous 547 1.0 0.80 (0.62–1.04) 0.67 (0.48–0.92)  
Lung metastasis 0.761
 Absent 469 1.0 0.92 (0.69–1.24) 0.66 (0.46–0.95)  
 Present 350 1.0 0.78 (0.54–1.12) 0.62 (0.40–0.94)  
Liver metastasis 0.098
 Absent 574 1.0 0.70 (0.54–0.91) 0.45 (0.32–0.62)  
 Present 245 1.0 1.39 (0.22–2.19) 1.46 (0.88–2.43)  
Bone metastasis 0.051
 Absent 382 1.0 0.83 (0.58–1.18) 0.76 (0.50–1.14)  
 Present 437 1.0 0.91 (0.68–1.23) 0.57 (0.39–0.82)  
Solitary lesion 0.062
 No 701 1.0 0.90 (0.72–1.14) 0.60 (0.45–0.80)  
 Yes 118 1.0 0.35 (0.14–0.86) 0.44 (0.17–1.13)  
Number of involved sites 0.331
 One 545 1.0 0.72 (0.57–0.99) 0.53 (0.38–0.74)  
 Two or more 274 1.0 1.11 (0.75–1.66) 0.84 (0.52–1.33)  
Treatment modality 0.055
 CT 607 1.0 0.92 (0.71–1.19) 0.56 (0.41–0.77)  
 CT + LT 212 1.0 0.74 (0.46–1.21) 0.89 (0.52–1.52)  
  1. OS overall survival; BMI body mass index; UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; HR hazard ratio; CI confidence interval
  2. aAdjusted for age, sex, UICC T category, UICC N category, onset of metastasis, solitary lesion, lung metastasis, liver metastasis, bone metastasis, number of involved sites, and treatment modality, excluding stratification covariate
  3. b P for interaction